Newly formed Cambridge, Mass.-based Proteostasis Therapeutics Inc. has raised $45 million in a Series A financing to develop therapies, which the firm has dubbed proteostasis regulators, to treat multiple genetic and degenerative disorders associated with protein homeostasis deficiencies, such as Alzheimer's disease, emphysema, Type II diabetes and Huntington's disease. (BioWorld Today)